Disclosure: This is an affiliate site. We may earn compensation from partners. Full disclosure | Medical disclaimer
Same price at every dose, with a steep commitment ladder
$139/mo
Compounded
Cash-pay
August 30, 2026
Raeliva markets itself on two things: clearly priced telehealth programs, and the same price at every dose. The second is genuinely useful — most compounded providers advertise a starting-dose rate that climbs as you titrate, and Raeliva does not.
Its compounded tirzepatide runs $299 a month month-to-month, as low as $242 a month on a six-month plan, and from $139 a month on a twelve-month plan. PolicyLab rated Raeliva 9.8 out of 10 and gave it the top spot in its 2026 tirzepatide compounding round-up.
The commitment ladder is steep — the gap between $299 monthly and $139 annual is more than two to one — so the headline figure and the flexible figure are very different products.
Raeliva dispenses compounded tirzepatide and semaglutide through licensed providers. Compounded drugs are not FDA-approved and the FDA does not evaluate them for safety, effectiveness or quality.
Online intake reviewed by licensed providers, with Raeliva describing its programs as clinically reviewed and clearly priced.
Adults meeting standard GLP-1 criteria as assessed by the reviewing provider.
Licensed providers guide the program and manage dosing, included in the plan price.
Not publicly listed as a standard requirement.
Compounding pharmacies. Raeliva does not publicly name its pharmacy partners.
Included with the plan, with expedited shipping cited by third-party reviewers. Injectable compounded GLP-1s require refrigerated cold-chain handling.
Provider-guided programs covering weight loss and longevity, with dose management included.
None published. Raeliva prices its programs as all-in monthly figures covering the medication, telehealth visit, prescription and shipping.
Included in the plan price, which stays flat across doses but varies enormously by commitment length.
The lowest rates require six- or twelve-month commitments. Confirm cancellation terms for your specific plan before purchase.
No published blanket refund policy. Compounded medication cannot be returned once dispensed.
Not accepted. Compounded GLP-1s are not FDA-approved and are not insurance-eligible.
Reimbursement for compounded medication is uncertain. Confirm with your plan administrator before purchase.
Pricing in this review reflects what Raeliva and named third-party sources published as of August 30, 2026. Telehealth pricing changes frequently — confirm the current figure at checkout before you buy.
People who want compounded tirzepatide specifically, expect to titrate to a high maintenance dose, and are confident enough to commit to a longer plan for the flat rate.
The two-to-one gap between the monthly and annual rate means the advertised $139 is only real if you prepay a year — and the FDA has narrowed the legal basis for compounded GLP-1s considerably since resolving the tirzepatide shortage in December 2024. Weigh that before committing twelve months.
Compounded tirzepatide injections are $299 a month month-to-month, as low as $242 a month on a six-month plan, and from $139 a month on a twelve-month plan. Plans include the medication, telehealth visit, prescription and expedited shipping.
No. Raeliva states the same price applies at every dose, so titrating up does not increase your monthly cost. That is a meaningful advantage over providers whose advertised rate applies only to the starting dose.
No. Raeliva dispenses compounded tirzepatide and semaglutide. Compounded drugs are not FDA-approved and the FDA does not evaluate them for safety, effectiveness or quality.
Raeliva is an operating telehealth service using licensed providers, and PolicyLab rated it 9.8 out of 10 and its top pick for 2026 compounded tirzepatide. It has less independent review coverage than more established competitors, and its medications are compounded rather than FDA-approved.
Only for the lowest rate. The $139 a month figure requires a twelve-month plan; six months runs from $242 and month-to-month is $299. That is a steep ladder, so decide based on the tier you will actually use.
No. Compounded GLP-1 medications are not FDA-approved and are not covered by insurance. Raeliva is a cash-pay service.
Every pricing and policy claim on this page traces back to one of these sources, checked on August 30, 2026.
Lowest published rate; requires annual commitment
Six-month plan
Month-to-month, no commitment
Raeliva states the same price applies at every dose
Verified August 30, 2026. Prices change often — confirm before purchase.
Share your experience with Raeliva to help others make informed decisions.
This review is for informational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. GLP-1 medications are prescription drugs with serious potential side effects and are not appropriate for everyone. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Compounded medications are not FDA-approved. The FDA does not evaluate compounded products for safety, effectiveness, or quality. Individual results vary. This page contains affiliate links, and we may earn compensation if you use them.
Date reviewed: August 30, 2026